Registration
Advertiser Disclosure

Biotechnology, Healthcare, and Research by Insmed

110
5.48
5.24 %
At close 11/04
USD
USD
NASDAQ
Daily range
102.83 Arrow from to Icon 110.75
Weekly range
102.83 Arrow from to Icon 115.85
Live Price Short-Term Long-Term Signals Earnings Price History News
Insmed reports third quarter earnings after stock ends session up 2.1%
  • Ivan Andriyenko
  • 29.10.2026
Insmed reports third quarter earnings after stock ends session up 2.1%
Insmed reported its third quarter earnings for 2026. The stock is up 2.1% on the day at $96.98.Insmed reported its 2026 third quarter earnings through an official company announcement. The post ...
Insmed appoints Paul Hudson and Utpal Koppikar to board after muted trading session
  • Mykhailo Ihnatenko
  • 20.10.2026
Insmed appoints Paul Hudson and Utpal Koppikar to board after muted trading session
Insmed appointed Paul Hudson, former CEO of Sanofi and Novartis Pharmaceuticals, and Utpal Koppikar, CFO of Verily Health, to its Board of Directors at a pivotal moment for the biotechnology ...
Insmed stock falls nearly 7% as CFO Sara Bonstein announces planned departure, stock pressured near support
  • Ciaran Ryan
  • 05.10.2026
Insmed stock falls nearly 7% as CFO Sara Bonstein announces planned departure, stock pressured near support
Insmed Incorporated (INSM) dropped 6.96% after the company announced Chief Financial Officer Sara Bonstein will step down in late 2026, with the company initiating a search for her successor. The ...
#Forecast
Insmed stock falls over 3% as sellers dominate despite strong drug revenues and regulatory wins
  • Oleg Tkachenko
  • 25.09.2026
Insmed stock falls over 3% as sellers dominate despite strong drug revenues and regulatory wins
Insmed Incorporated (INSM) slipped 3.38% after sellers dominated today's session, even as the company recorded strong second-quarter drug revenues and obtained fresh regulatory approvals. The down ...
#Forecast
Insmed receives FDA Priority Review for MAC lung therapy after stock ends session down 3%
  • Mira Kyivska
  • 21.09.2026
Insmed receives FDA Priority Review for MAC lung therapy after stock ends session down 3%
Insmed said U.S. regulators have granted Priority Review to its supplemental New Drug Application for a lung disease therapy. The stock is down 3% on the day at $120.The company said the FDA has ...
Insmed stock jumps nearly 4% as peak sales guidance for BRINSUPRI tops $7 billion
  • Mira Kyivska
  • 09.09.2026
Insmed stock jumps nearly 4% as peak sales guidance for BRINSUPRI tops $7 billion
Insmed Incorporated (INSM) surged 3.71% after the company raised its peak sales guidance for BRINSUPRI above $7 billion, reflecting accelerating commercial momentum and renewed investor inflows. ...
#Forecast
Insmed stock holds below key averages with downside risk remaining elevated
  • Jose Antonio Gastelum
  • 06.08.2026
Insmed stock holds below key averages with downside risk remaining elevated
Insmed published its second-quarter 2026 earnings results in a social post Tuesday. At the same time, Insmed stock edges higher on the day, trading at $99.02.The company posted its own Q2 2026 ...
Insmed stock gains 2.18% as commercial leadership appointment boosts respiratory segment outlook
  • Sholanke Dele
  • 01.07.2026
Insmed stock gains 2.18% as commercial leadership appointment boosts respiratory segment outlook
Insmed (INSM) stock is trading at $107.02, up 2.18% on the day and maintaining its position above key moving averages. The price holds in the middle of today’s range, ...
#Forecast
Who We Are
Business Solutions
For Users
TU News
Popular Sections
Disclosures
CONTACT US
Legal
We are in Social Media
© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186
  • Risk disclosure:

    Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

    That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

  • Disclaimer:

    Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

    Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

  • Disclosure of advertisers and revenues:

    All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

    Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.

onepercentfortheplanet.org https://gdpr.eu/ GDPR World Association of News Publishers